This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Third View: Delving into the phase 1 clinical trial of Amgen's MariTide for the treatment of obesity.
Ticker(s): AMGN, NVO, LLYWho's the expert?
Institution: UC San Francisco
- Chair in Diabetes Research and Associate Professor of Medicine at the University of California San Francisco.
- Manages the care for 200 diabetes patients per month, with over a few thousand overall patients in the practice as part of a large County Hospital System.
- His work focuses on determining links between dietary nutrients, nutrient metabolism, inflammation, and fibrosis in insulin-sensitive tissues, and how these links impact the development of diabetes type 2.
Interview GoalTo discuss the current standard of care and the potential of MariTide (maridebart cafraglutide) being developed by Amgen for the treatment of obesity.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
